Free Trial
NASDAQ:XAIR

Beyond Air Q2 2027 Earnings Date & Estimates

Beyond Air logo
$2.36 +0.04 (+1.90%)
As of 10:33 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Beyond Air is estimated to report Q2 2027 earnings on Wednesday, November 11, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Upcoming Earnings Announcement

Quarter
Q2 2027
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET

What Analysts Expect from Beyond Air in Q2 2027

Beyond Air is expected to post earnings of -$3.31 per share on revenue of $2.16 million. In the same quarter a year earlier Beyond Air reported -$25.00 per share on revenue of $1.82 million. Beyond Air last reported on August 13, 2026, posting -$11.00 per share and missing the -$10.80 consensus estimate. Beyond Air has beaten the consensus EPS estimate in 2 of its last 7 quarters.

Consensus Estimates

Consensus EPS
-$3.31
Expected Revenue
$2.16 million
Prior-Year EPS
-$25.00
Prior-Year Revenue
$1.82 million
Expected Revenue Growth
+19.0%

Recent Track Record

Last Reported
Q1 2027
Last Quarter EPS
-$11.00 (Missed by -$0.20)
Last Quarter Revenue
$1.77 million
EPS Beat Rate
2 of last 7 quarters

Beyond Air Q2 2027 Earnings FAQ

Beyond Air (NASDAQ:XAIR) is estimated to report Q2 2027 earnings on Wednesday, November 11, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Beyond Air's Q2 2027 earnings conference call is scheduled for Wednesday, November 11, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Beyond Air to post earnings of -$3.31 per share for Q2 2027.

The consensus revenue estimate for Beyond Air is $2.16 million for Q2 2027.

Beyond Air Earnings Headlines

Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.tc pixel
See More Beyond Air Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Beyond Air? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Beyond Air and other key companies, straight to your email.

About Beyond Air

Beyond Air (NASDAQ:XAIR) is a medical technology and biopharmaceutical company focused on developing nitric oxide (NO) therapies and delivery systems for respiratory diseases and other serious medical conditions. Its platform is designed to generate NO from ambient air at the point of care, potentially reducing reliance on traditional high-pressure gas cylinders.

The company’s primary product family is LungFit, a series of compact NO delivery systems intended for use in hospital and clinical settings. LungFit PH is designed to deliver inhaled nitric oxide to term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension. Beyond Air has also developed additional LungFit systems for other respiratory applications, including systems intended for use with ventilated patients.

Beyond Air is also researching the use of high concentrations of inhaled nitric oxide as a potential treatment for respiratory infections and certain solid tumors through its Beyond Cancer program. The company is headquartered in Garden City, New York, and its products and development programs are focused primarily on hospital-based and specialty-care markets. Steven A. Lisi serves as the company’s chairman and chief executive officer.

View Beyond Air Profile